Explore Early Signs of Molybdenum Cofactor Deficiency in Infants

Molybdenum cofactor deficiency is a rare genetic disorder involving impaired production of molybdenum cofactor, a substance required for the normal function of several enzymes. When the cofactor is deficient, certain substances can accumulate in the body and contribute to neurological injury. Severe forms commonly become apparent during the neonatal period or early infancy.

Early Signs of Molybdenum Cofactor Deficiency in Infants

Infants with early onset disease may appear healthy at birth and then develop symptoms within the first days or weeks. Neurological manifestations are often prominent and can progress quickly. The timing and combination of symptoms can vary, but several findings may raise clinical suspicion.

Common early signs can include:

• Seizures: Seizures are among the most frequent initial signs and may be difficult to control with standard antiseizure medicines.
• Feeding difficulties: An infant may have difficulty sucking, swallowing, or maintaining adequate feeding.
• Abnormal muscle tone: Some infants develop low muscle tone, particularly around the trunk, while others develop increased tone or rigidity.
• Breathing problems: Episodes of apnea can occur, particularly during the early neonatal period.
• Exaggerated startle response: A small proportion of affected infants may react unusually strongly to sounds, touch, or movement.
• Developmental concerns: Progressive neurological involvement can lead to severe delays in motor and developmental skills.

These symptoms are not specific to molybdenum cofactor deficiency and may occur with other neurological, metabolic, or genetic conditions. Therefore, their presence does not by itself establish a diagnosis.

Diagnosis and Importance of Early Recognition

Diagnosis generally involves a combination of clinical assessment, biochemical testing, brain imaging when appropriate, and genetic evaluation. Laboratory findings that may support the diagnosis include increased sulfite-related metabolites and xanthine or hypoxanthine in urine, together with low blood uric acid levels. Genetic testing can identify disease-causing variants in genes such as MOCS1, MOCS2, and GPHN.

Important considerations during evaluation include:

• Detailed clinical assessment: Healthcare professionals review seizure patterns, feeding problems, muscle tone, breathing episodes, and developmental changes.
• Biochemical testing: Specialized metabolic tests can help distinguish molybdenum cofactor deficiency from other inherited metabolic disorders.
• Genetic testing: Molecular testing can help confirm the underlying genetic cause and distinguish different forms of the condition.
• Brain imaging: MRI findings may provide additional information about neurological changes and can help with the differential diagnosis.
• Family history: Information about previous affected pregnancies, infants, or known inherited conditions may help guide genetic evaluation.

Early recognition is important because severe molybdenum cofactor deficiency can progress rapidly during infancy. However, similar symptoms can occur in several other disorders, so diagnosis requires appropriate medical evaluation rather than relying on symptoms alone.

Understanding the early signs of molybdenum cofactor deficiency can help families and healthcare professionals recognize when further evaluation may be appropriate. Persistent seizures, feeding difficulties, abnormal muscle tone, apnea, or unusual neurological changes in a newborn should receive prompt medical attention. A qualified healthcare professional can determine which diagnostic tests are appropriate and whether a metabolic or genetic disorder should be considered.